Expression of the human oncogene TCL1 in transgenic mice produces B-cell tumors that resemble chronic lymphocytic leukemia (CLL) suggesting its role in B-cell tumorigenesis. To clarify the expression pattern and regulation of TCL1 in CLL, we assessed 213 primary tumors by immunohistochemistry (IHC), flow-cytometry and/or Western blot, using a new monoclonal antibody. TCL1 protein was detectable in the majority of CLL (90% by IHC) but showed marked variations across cases with virtual absence in approximately 10% of tumors. Higher TCL1 levels correlated with markers of the 'pre-germinal center' CLL subtype including unmutated VH status (P ¼ 0.005), ZAP70 expression (P ¼ 0.007), and presence of chromosome 11q22-23 deletions (P ¼ 0.04). Intratumoral heterogeneity in TCL1 levels was also prominent and explained in part by markedly lower TCL1 expression in proliferating tumor cells. In vitro exposure of CLL cells to interleukin-4 (but not other growth factors) produced progressive and irreversible decrease in TCL1 protein levels in association with the onset of proliferation. TCL1 expression patterns in CLL are complex and highly dynamic and appear to reflect both the histogenetic subtypes of the disease and the growth parameters of individual tumors. The observed regulation pattern suggests that TCL1 may exert its effects predominantly in the unmutated/ZAP70-positive tumor subset.
Introduction
T-cell leukemia 1 (TCL1) was identified as the oncogene located at the 14q32.1 chromosome breakpoint region in T-cell prolymphocytic leukemia (T-PLL). [1] [2] [3] In T-PLL, TCL1 is overexpressed as a result of either an inversion or a reciprocal translocation, by juxtaposition to the T-cell receptor (TCR) a/d or TCR-b promoter/enhancer elements. 4, 5 TCL1-transgenic mice develop T-cell tumors after prolonged T-cell hyperplasia, 6 with a clinical course and phenotype resembling human T-PLL, which overexpress TCL1 in 80% of the cases. 1, [7] [8] [9] Besides its tumorigenic role in T-PLL, TCL1 is normally expressed in the CD3-CD4-CD8-subset of thymic precursors in the T-cell lineage, the plasmacytoid subset of dendritic cells and B cells up to the germinal center (GC) stage of maturation. 3, [10] [11] [12] TCL1 has also been shown to be highly expressed in most Bcell tumors, however, chromosome aberrations that constitutively activate TCL1 are not found and thus its role as a B-cell oncogene is unclear. [13] [14] [15] [16] [17] [18] However, when driven by IgH Em enhancer elements, human TCL1 overexpression in mice produces B-cell tumors preceded in some cases by preneoplastic CD5 þ /IgM þ B-cell expansions that resemble early chronic lymphocytic leukemia (CLL). 15, 19, 20 To clarify TCL1's role in human CLL, we present here the first complete assessment of the regulation of TCL1 in the different molecular and immunophenotypic subsets of CLL. We note that TCL1 expression is variable, with a substantial minority of CLL being negative or only weakly positive for TCL1, including a differential expression related to differentiation stage. We further describe intratumoral variations in TCL1 levels that are related to cellular proliferative state and can be replicated during in vitro culture.
Materials and methods

Patient samples
Material was acquired in accordance with an institutional review board-approved protocol and the provisions of the Helsinki protocol. The study included archived CLL and small lymphocytic lymphoma (SLL) tissue samples as bone marrow biopsies and lymph node specimens (in cases of SLL) accessioned at The University of Texas M. D. Anderson Cancer Center, Houston, between 1981 and 2004. The routinely processed paraffin-embedded material for immunohistochemical staining included conventional tissue sections and tissue microarrays (TMA). In addition, fresh specimens included tumor cells isolated (details below) from masses or peripheral blood (PB) samples with lymphocytes comprising X90% of all white blood cells. Cytogenetic analysis was performed on parallel bone marrow aspirate samples, including standard metaphase karyotypes and application of a multicolor probe FISH-panel (Vysis, Downers Grove, IL) that detects chromosome 11q22.3 (ATM gene), 17p13.1 (P53 gene), the alpha satellite centromeric region of chromosome 12 (D12Z3), the D13S319 locus at 13q14.3 (located between RB1 and D13S25), and the 13q34 region (LAMP1 gene).
Isolation and culture of primary tumor cells
Primary tumor cells were obtained from patient samples after isolation by Ficoll Paquet Plus (Sigma-Aldrich, St Louis, MO) density centrifugation. The material included PB and nodal suspensions, both of which were further purified using the RosetteSept Human B-cell enrichment cocktail (StemCell Technologies Inc., Seattle, WA). Remaining macrophages were allowed to attach to the cultures flasks and separated before initiation of experimental conditions. Purity was assessed by flow cytometry. For in vitro stimulation, the isolated cells in culture media (15% fetal calf serum in RPMI) were subjected to the following conditions: soluble CD40-ligand (L) (100 ng/ml) with or without interleukin (IL)-4 (20 ng/ml) with addition of single or combinations of IL-10 (20 ng/ml), IL-6 (20 ng/ml), interferon-a (100 ng/ml) (all PeproTech, Rocky Hill, NJ) and mouse F(ab) 0 2 anti-human IgM (0.25 mg/ml; Southern Biotech, Birmingham, AL). Cells were harvested at multiple time points starting from 24 h to 45 days post-initiation.
Production of TCL1-antibody
For TCL1 protein detection, an antipeptide monoclonal antibody (clone 1-21) was produced. Hybridoma supernatants were desalted, buffer-exchanged and stored in 1% w/v BSA plus 0.05% Na-azide. The specificity of this antibody was confirmed both by Western blot analysis of whole cell lysates from Jurkat cells transfected with a TCL1-cDNA containing construct and by proteomic methods.
Construction of tissue microarrays
A manual tissue microarrayer (Beecher Instruments, Silver Spring, MD) was used to produce TMA with representative cores (sampled in duplicates) from paraffin-embedded archival tissue blocks of formalin-fixed material. Sections, 4 mm thick, of the TMA were cut with a standard microtome and subjected to immunohistochemical staining.
Immunohistochemistry
Staining of deparaffinized whole tissue or TMA sections was performed following antigen retrieval. The antibodies included TCL1 (1-21, dilution 1:500), CD45RO (UCHL1, Dakocytomation, Carpinteria, CA, 1:2000), ZAP70 (2F3.2, Upstate, Charlottesville, VA, scored on a 3-tier scale with 0-absent, 1-weak, 2-uniform-strong, 1:100) and surface (s) IgM (polyclonal goat, Vector Laboratories, Burlingame, CA, 1:3000, scores as for TCL1, see below). For detection, avidin-biotinylated peroxidaseconjugated reagents (Vectastain Elite, Vector Laboratories or LSAB þ kit, Dakocytomation) with 3,3 0 -diaminobenzidine tetrahydrochloride as the chromogenic substrate were used. TCL1 immunostains were graded independently by two investigators on a 4-tier scoring system, as follows: 0-negative, 1-less than 5% of tumor cells positive, 2-partially positive in up to 50% of tumor cells, and 3-strongly positive in over 50% of tumor cells. A Nikon Labophot 2 microscope (Nikon, Melville, NY) with an Olympus DP11 camera (Olympus, Melville, NY) was used for photomicrographs, which were assembled into composites using Adobe Photoshop 7.0 software (Adobe, San Jose, CA). Giemsa-Wright stainings on cytospins were performed according to routine protocols.
Confocal microscopy
Cytospins were fixed in cold methanol for 5 min, permeabilized for 10 min in PBS with 0.2% Triton X-100 and 1% normal goat serum (NGS). After blocking for 30 min in 5% NGS, 0.5% bovine serum albumin (Fraction V) in PBS, the samples were probed with the antibodies. Fluorescence was detected using the Olympus confocal microscope (Model IX71FVSF-2; Olympus America Inc., Melville, NY). Primary antibodies included TCL1 (1:50, clone 1-21) and PCNA (1:500, clone PC10, Zymed, Carlsbad, CA). The secondary antibodies used were Cy3-conjuated AffiniPure Donkey Anti-Rabbit IgG (1:100) and Fluorescein (FITC)-conjugated AffiniPure Donkey Anti-Mouse IgG (1:25), both from Jackson Immuno Research Laboratories, West Grove, PA.
Flow cytometry
Three-and four-color flow cytometric immunophenotyping was performed on samples (following a standard red cell lysis method for blood samples) using mouse monoclonal antibodies directed against CD45 (PerCP-conjugated) as well as combinations of antibodies against CD3, CD10, CD19, and sIgM (all from Becton-Dickinson, San Jose, CA). Analysis was performed using FACScan or FACScalibur cytometers. Negative staining levels were set by comparison with an isotype control antibody. For staining of the intracellular TCL1 protein in combination with detection of Propidium Iodide (PI) incorporation, we used our monoclonal anti-TCL1 antibody (clone 1-21) and PI/RNAse (Molecular Probes/Invitrogen, Carlsbad, CA) in a modified protocol applying the Cytofix/Cytopermt kit (Becton-Dickinson). FITC-conjugated rat anti-mouse Igk antibody (BectonDickinson) was used as a secondary antibody. The protocol setup was done using an established 13 TCL1 full-length antibody for titration. Each experiment included stably positive and negative (as previously analyzed by Western blot) cell lines as well as a mouse IgG1k immunoglobulin isotype control.
Western blot analysis
Whole cell lysates were prepared from freshly isolated and cultured tumor cells. The cell lysis buffer was comprised of 25 mM Hepes, pH7.7, 400 mM sodium chloride, 1.5 mM magnesium chloride, 2 mM ethylenedinitrilotetraacetic acid (EDTA), 0.5% Triton X-100) and contained the following protease/phosphatase inhibitors: 3 mM dithiothreitol (DTT), 20 mM beta-glycerophosphate, 2 mM sodium orthovanadate (Na 3 VO 3 ), 5 mM sodium fluoride, 25 mM para-nitrophenylphosphate disodium (PNPP), 0.1 mM phenyl methyl sulfonyl fluoride (PMSF) as well as the completet protease inhibitor cocktail (Roche, Germany). 50 mg of protein were separated by SDS polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. Blots were incubated overnight at 41C with the primary antibodies TCL1 (1-21, dilution 1:2000), pAKT Ser473 (polyclonal rabbit, Cell Signaling Technology Inc., Beverly, MA, 1:1000), p65 NFkB (F-6, Santa Cruz, 1:500), AKT1/2 (Santa Cruz, 1:1000) and anti-b-actin (AC-15, Sigma, 1:10 000). The peroxidase reaction was detected using the ECL system (Amersham, Piscataway, NJ).
MTT proliferation assays
Colorimetric proliferation assays using the CellTiter96 s assay (Promega, Madison, WI) were performed according to the manufacturer's instructions. Shortly, 100 ml of cells in culture media were seeded at a density of 3 Â 10 5 cells/ml into duplicate wells of a 96 flat bottom well plate. After 1 h at 371C, 20 ml of CellTiter96 s AQ eous reagent were added and readings were performed after 4 and 8 h on a mQuant 96-well plate reader (BIO-TEK Instruments, Winooski, VT). Individual absorbances at 490 nm (690 nm reference) wavelength were corrected using blanks with only culture media and the averaged data charted. Experiments were repeated at least twice.
IgH V H mutation status in CLL RNA was extracted from PB or bone marrow samples using Trizol reagent. Following reverse transcription using Superscript II (Invitrogen), PCR was performed using either a JH or a CH primer along with consensus VH1-VH6 leader primers, as described previously. 21 Products were directly sequenced using the dideoxy chain termination method on a 3100 genetic analyzer (ABI, Foster City, CA). Sequences were compared to the IMGT IgH database using DNAPLOT software (available at http://www.dnaplot.de) and the percentage divergence from germline sequence was calculated over the entire IgV H coding region (codons 1-94). A cutoff of 42% divergence was used to define mutated vs unmutated status. Mutation rate was also analyzed as a continuous variable.
Statistics
Based on the 4-tier ordinal scale of TCL1 levels, correlations were calculated using the w 2 test for categorical variables. The Kruskal-Wallis test was used to compare continuous variables such as percent deviation from the germ-line sequences in the somatic hypermutation analysis between the four TCL1 expression groups. When TCL1 scores 0 and 1 were grouped as 'low' vs 'high' for scores 2 and 3, correlations were performed by w 2 and Fisher's exact tests. The Mann-Whitney test was used for comparison of continuous variables between the two TCL1 expression groups. Computations were done using the STATIS-TICA software (StatSoft, Tulsa, OK), and a P-value of o0.05 was considered significant.
Results
The level of TCL1 protein in CLL correlates with specific tumor subgroups
To explore a role for TCL1 as an oncogene in human CLL, we assessed the pattern of TCL1 expression in primary CLL samples using flow cytometry, paraffin-section immunohistochemistry (IHC) and/or Western blot analysis. A total of 213 cases (204 CLL and 9 SLL) were analyzed by one or more methods. TCL1 expression levels by all techniques ranged from complete absence to strong uniform expression, with a few cases showing very high TCL1 levels comparable to those found in T-PLL. Absence of TCL1 was found in 12% (4/34) of cases analyzed by flow-cytometry, 10% (14/135) by IHC and 14% (5/35) assessed by Western blot (Figure 1a and c, Table 1 ).
We then correlated TCL1 levels with different immunophenotypic and molecular subsets of CLL (Figure 1b and c, Table 2 ). Cases that strongly expressed TCL1 by either flow cytometry or IHC were associated with higher levels of sIgM (P ¼ 0.03). CLL that lacked ZAP70 protein in tumor cells by IHC preferentially showed absence or weak expression of TCL1 (P ¼ 0.007, Figure 1b) .
Strong expression of TCL1 was less frequent in CLL that had VH gene mutation rates above 2% (11/29, 38%) as compared to those that were unmutated (29/38, 76%; P ¼ 0.005, Figure 1b) . There was also a statistically significant inverse correlation between the level of TCL1 expression and the VH mutation rate for any given case (P ¼ 0.01, Figure 1a (I)-(III), b, Table 2 ). Among cases that strongly expressed TCL1, there was a significantly higher incidence of chromosome 11q22/ATM loss or monosomy 11, as determined by FISH analysis and/or metaphase karyotype analysis (P ¼ 0.04, Figure 1b) .
Intratumoral heterogeneity in TCL1 levels is related to microenvironmental location and proliferation
In addition to the variability of TCL1 expression among cases of CLL, we also observed striking intratumoral heterogeneity in TCL1 levels. In tissue sections, we noted that TCL1 immunohistochemical expression was related to microenvironmental locations in lymph node and bone marrow. For example, in Left: CLL cases with absent/low TCL1 levels (scores 0 and 1) were associated with a higher VH mutation rate (median 3.2% divergence from germline) as compared to cases expressing TCL1 at higher levels (scores 2 and 3, median 0.3%; P ¼ 0.01). Bars indicate the 5-95th percentile around the 25-75th percentile box that includes the median. Right: the proportion of cases with high TCL1 levels (black bars) in CLL with unmutated VH genes (o2% divergence) is approximately twice as high as those in the VHmutated group (P ¼ 0.005). High levels of TCL1 are associated with CLL expressing ZAP70 (P ¼ 0.007) and tumors with chromosome 11 deletion or loss of the 11q22-23 locus (P ¼ 0.04). (C) TCL1 protein levels in CLL detected by Western blot analysis also reveal a correlation with VH gene mutation status (compare to Table 2 ).
bone marrow infiltrates of CLL, there was a stronger TCL1 expression among the interstitial tumor component as compared to the nodular areas in most cases (Figure 2a) . In lymph nodes involved by CLL/SLL, TCL1 was strongly expressed in the small cell component of the proliferation centers, but was dim/ negative in the mitotically active paraimmunoblasts in these areas (Figure 2b ). This variation in TCL1 levels was further related to proliferation by double-label IHC with the proliferation marker PCNA and TCL1, which confirmed this inverse relationship (Figure 2c ). Dual-staining IHC revealed in some cases that TCL1 downregulation in the tumor cells was most prominent within tissue sites that were rich in tumor-associated T-cells (not shown).
In vitro stimulation by IL-4 induces proliferation and differentiation of CLL tumor cells along with downregulation of TCL1 expression
The microenvironmental variations seen in vivo and the association of dimmer TCL1 with the post-GC variant of CLL suggested a dynamic regulation in CLL related to differentiation state. To explore this phenomenon, we compared the effects of various B-cell proliferative stimuli and differentiation signals on TCL1 levels in CLL cells in culture. As defined by predominantly nodal disease; cases not included in CLL category. Overall, there also was a tendency of higher TCL1 levels being associated with higher percentages of CD38 positive cells as analyzed by flow cytometry (Mann-Whitney P ¼ 0.1).
a Same results observed when using a 4-tier scale (TCL1 levels 0-3) or grouping TCL1 into absence vs presence. 
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When analyzed by Western blot and flow-cytometry, a marked downregulation of TCL1 was observed in cultures exposed to IL-4 alone or in combination with other cytokines for at least 10-14 days. No significant effects on TCL1 levels were seen with interferon-a, IL-6, CD40L or anti-IgM alone or in combination (Figure 3 ). Overall TCL1 levels were reduced to 45-55% after 14 days and further decreased to 25% after 21 days. This reduction of TCL1 expression appeared irreversible in that removal of IL-4 followed by up to 25 additional days of culture did not result in rebound of TCL1 levels.
These IL-4-containing culture conditions were also the most potent in inducing proliferation in long-term CLL cultures (Figure 3) . IL-4 treatment also induced cell differentiation as confirmed by the appearance of plasmacytoid forms (Figure 3 , Giemsa-Wright staining) and changes in sIgM levels by flow cytometric analysis (not shown). Confocal microscopy on TCL1/ PCNA double stains of these IL-4-treated cultures confirmed an increase in proliferating TCL1-dim PCNA þ cells compared to the predominance of TCL1-bright, largely noncycling cell populations seen at earlier timepoints ( Figure 3 ).
Discussion
As transgenic expression of human TCL1 can produce CLL-like tumors in mice, we assessed how TCL1 is regulated in human CLL. Using three different methodologies, we observed heterogeneity in TCL1 levels that was in part explained by correlation with known subtypes of CLL. Higher TCL1 levels were more strongly correlated with markers of the 'pre-GC' subset of CLL, including unmutated VH gene status and higher ZAP70 expression levels. However, we also noted marked intratumoral heterogeneity in TCL1 that has not been reported previously and which could be mimicked by culture of CLL cells with IL-4. In normal B-cells, TCL1 is regulated according to developmental stage with strong expression in resting B-cells, and loss of expression at the GC stage. Several previous surveys of B-cell tumors have demonstrated that this developmental pattern of regulation is largely preserved with pre-GC tumor types (e.g. mantle cell lymphoma) strongly expressing TCL1 and post-GC subsets (e.g. multiple myeloma) being essentially negative for TCL1. [13] [14] [15] [16] [17] Reports of TCL1 protein expression in CLL have been limited to a few small immunohistochemical studies without immunophenotypic, genotypic, or molecular correlations and did not comment on intratumoral regulation of TCL1 levels. 13, 14, 16 Here, we show that CLL also largely maintains the normal Bcell developmental pattern of TCL1 regulation with lower levels in the post-GC/mutated tumor subset. Indeed, we found that 10-14% of CLL are TCL1 negative and an additional proportion (27% by IHC) shows low protein levels. Occasional cases of CLL that lacked TCL1 were associated with rearrangements at chromosome 14q32 (Table 2) , suggesting a potential role for deletion of the TCL1 locus in loss of expression in those cases.
Besides, this B-cell stage-specific variation in TCL1 expression, we also report for the first time marked intratumoral heterogeneity in TCL1 levels. Variations in TCL1 expression detected by immunostaining strongly suggest that TCL1 protein levels undergo cyclical changes during tumor cell growth. We noted that TCL1 was expressed at low levels in the actively proliferating tumor components, which was most pronounced in the CLL proliferation centers. Other variations in TCL1 levels appear related to microenvironmental location. These changes likely reflect the dynamic effects of tissue-derived cytokines, as TCL1 levels varied based on the density of tumor-associated Tcells. Effective silencing of TCL1 expression in cultured primary CLL was predominantly driven by the presence of IL-4, which appeared to provide both proliferative and differentiation signals. Therefore, IL-4 derived from tumor-associated T-cells is a likely candidate for mediating TCL1 silencing in vivo.
The finding that TCL1 in CLL retains a pattern of regulation has important implications for the role of TCL1 as an oncogene. In particular, the modulation of TCL1 expression observed here is distinctly different from what is seen in T-cell tumors. In T-PLL, TCL1 acts as a classical oncogene by insertional activation through T-cell receptor regulatory elements that drive a relatively constant high level of expression in the transformed T-cell population. 4, 5 This situation is similar to that seen in the B-cell leukemias that result from ectopic human TCL1 in murine B-cells. [1] [2] [3] 19 In this respect, the role of TCL1 in driving the emergence of B-cell tumors in mouse models may be partly a consequence of the imposed constitutive expression. Thus, future studies on the role of TCL1 in human B-cell oncogenesis, including the strongly TCL1-positive 'pre-GC' subset of CLL, must take into account its regulated expression.
